NORTH BRABANT

Onera raises over €30M in Series C funding

Retrieved on: 
Tuesday, January 16, 2024
Digital health, Sleep, PSG, DACH, Health, Partnership, BOM, ONERA, American Academy, Medicine, Generative grammar, Medtech, Polysomnography, AASM, Growth, Pharmaceutical industry

Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round.

Key Points: 
  • Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round.
  • Eindhoven – January 16, 2024 – Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.
  • This latest funding round brings Onera’s total investment to date to more than €55 million.
  • As part of this transaction, Drew Burdon and Michaël Vlemmix will join Onera Health’s Board of Directors.

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

Retrieved on: 
Friday, November 17, 2023
Kidney disease, Fistula, Patient, FIH, Endothelium, Infection, Dialysis, AVF, AVG, Pharmaceutical industry

The data was presented yesterday by Prof. Dr. Frans Moll at the 50th Annual VEITHsymposium in New York.

Key Points: 
  • The data was presented yesterday by Prof. Dr. Frans Moll at the 50th Annual VEITHsymposium in New York.
  • At 12 months, 100% secondary patency, 78% primary assisted patency and 0% infections were observed in data from 20 patients implanted with the aXess conduit.
  • This performance builds on the very encouraging 6-month data presented in April 2023 at the Vascular Access Society Congress in Porto, Portugal.
  • aXess is a restorative conduit which enables the creation of a new, long-term living vessel for hemodialysis vascular access.

Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing

Retrieved on: 
Monday, August 14, 2023
CABG, European Innovation Council, Civil service commission, Patient, Series, FIH, EIC, European Commission, Pharmaceutical industry, European

Today’s extension from EIC and the closure of the Series D2 financing round announced in February 2023 , brings the total amount raised to €44.5 million.

Key Points: 
  • Today’s extension from EIC and the closure of the Series D2 financing round announced in February 2023 , brings the total amount raised to €44.5 million.
  • The additional funding will support the continued clinical development of Xeltis’ transformative implants.
  • Svetoslava Georgivea, Chair of the EIC Fund Board said: “It is the ambition of the European Innovation Council (EIC) Fund to invest in European companies that develop cutting-edge technologies with high impact.
  • The €15 million consists of a €2.5 million grant and a €12.5 million equity investment through the EIC Fund.

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

Retrieved on: 
Friday, April 28, 2023
University of Insubria, Infection, Kidney disease, Surgeon, University, Chronic kidney disease, Congress, Patient, Risk, FIH, CKD, Vascular surgery, Fistula, Medical imaging, Birth control, Pharmaceutical industry, EU

aXess graft demonstrated excellent patency, low rates of infection and re-intervention

Key Points: 
  • aXess graft demonstrated excellent patency, low rates of infection and re-intervention
    EINDHOVEN, The Netherlands – 28 April 2023, Xeltis, a developer of transformative implants that enable the natural creation of living and long-lasting vessels and valves, today presents highly-encouraging six-month data from its first-in-human (FIH) aXess vascular graft trial ( NCT04898153 ) at the 13th Congress of the Vascular Access Society in Porto, Portugal.
  • aXess is a vascular access graft for patients with chronic kidney disease (CKD) requiring hemodialysis.
  • In six-month data from the FIH trial, the aXess graft demonstrated high patency rates (80% primary patency, 95% primary assisted patency, 100% secondary patency).
  • The full data will be presented by Matteo Tozzi, Professor of Vascular Surgery, University of Insubria, Italy, in a presentation entitled: aXess Vascular Graft – FIH trial 6-month outcomes today at 09:05 WEST.

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices

Retrieved on: 
Tuesday, February 21, 2023
CKD, Patient, ETR, Netherlands, Chronic kidney disease, Quality of life, DaVita Inc., Pharmaceutical industry

This fundraising round will enable Xeltis to progress its key clinical programs into pivotal trials, as it aims to give patients around the world access to the world’s most advanced restorative cardiovascular devices.

Key Points: 
  • This fundraising round will enable Xeltis to progress its key clinical programs into pivotal trials, as it aims to give patients around the world access to the world’s most advanced restorative cardiovascular devices.
  • Xeltis’ breakthrough technology is focused on restoring the body’s natural cardiovascular functions, with numerous potential applications.
  • Xeltis’ most advanced program, aXess, is a vascular access graft for patients with chronic kidney disease (CKD) requiring hemodialysis.
  • We remain focused on progressing our aXess clinical trials, as well as exploring our next steps in other indications,” commented Eliane Schutte, CEO of Xeltis.

LUMICKS Continues Efforts to Offset CO2 Emissions Generated by Global Travel by Planting Trees on Former Farmland

Retrieved on: 
Wednesday, June 16, 2021
Climate change policy, Greenhouse gas emissions, Emissions reduction, Carbon finance, Environmental impact of the energy industry, Articles, Energy, Carbon neutrality, Climate change

To combat the unavoidable emissions their travel generated, the company sponsored the planting of 5,500 trees on former farmland.

Key Points: 
  • To combat the unavoidable emissions their travel generated, the company sponsored the planting of 5,500 trees on former farmland.
  • Over the next 30 years, those trees are expected to capture 1-1.5 times the CO2 emissions of the company's 2019 travel.
  • "The trees planted to date are helping to compensate for emissions resulting from our 2019 travel," said LUMICKS Sales and Marketing Director Willem Peutz.
  • In addition to this project, LUMICKS previously collaborated with Trees for All to offset its carbon emissions in 2018 from flying.

LUMICKS Continues Efforts to Offset CO2 Emissions Generated by Global Travel by Planting Trees on Former Farmland

Retrieved on: 
Wednesday, June 16, 2021
Climate change policy, Greenhouse gas emissions, Emissions reduction, Carbon finance, Environmental impact of the energy industry, Articles, Energy, Carbon neutrality, Climate change

To combat the unavoidable emissions their travel generated, the company sponsored the planting of 5,500 trees on former farmland.

Key Points: 
  • To combat the unavoidable emissions their travel generated, the company sponsored the planting of 5,500 trees on former farmland.
  • Over the next 30 years, those trees are expected to capture 1-1.5 times the CO2 emissions of the company's 2019 travel.
  • "The trees planted to date are helping to compensate for emissions resulting from our 2019 travel," said LUMICKS Sales and Marketing Director Willem Peutz.
  • In addition to this project, LUMICKS previously collaborated with Trees for All to offset its carbon emissions in 2018 from flying.

dpiX and TNO at Holst Centre Sign MOU to Formalize Partnership

Retrieved on: 
Tuesday, March 9, 2021
Musicians, British musicians, Classical musicians, IMEC, TNO, Gustav Holst

With TNO at Holst Centre as a partner, well be able to expand even further.

Key Points: 
  • With TNO at Holst Centre as a partner, well be able to expand even further.
  • This unique partnership combines TNO at Holst Centres research and prototyping capabilities with the engineering and fabrication facilities of dpiX.
  • The new MOU represents the formalization of an ongoing partnership between dpiX and TNO at Holst Centre.
  • Holst Centre is an independent research and innovation centre, jointly operated by imec and TNO.

DGAP-News: ENCAVIS AG expands its participation in its solar park portfolio in The Netherlands

Retrieved on: 
Wednesday, January 27, 2021
Articles, Infrastructure, Photovoltaic power station, Photovoltaics, Solar energy, Energy, Renewable energy, Solar power in California

Encavis Group now owns close to 99% of the solar park portfolio of around 106 megawatts (MW) in The Netherlands.

Key Points: 
  • Encavis Group now owns close to 99% of the solar park portfolio of around 106 megawatts (MW) in The Netherlands.
  • Encavis AG had already increased its ownership to 100% in the Spanish large-scale solar project La Cabrera (200 MW total capacity), the Brandenburg/Havel solar park (18.7 MW total capacity), the Bitterfeld solar park (6 MW total capacity) as well as in 12 further solar parks in France with a total capacity of 75 megawatts (MW) in fiscal 2020.
  • Encavis AG currently owns all British, French, Italian and nearly all Dutch and German solar parks (both are close to 99%) nearly completely.
  • Whenever ENCAVIS has the opportunity to acquire missing minority shares in our solar park portfolio on economically convincing terms, we will take advantage," Dr Christoph Husmann, CFO of Encavis AG, underlined the latest acquisition.